Physician profile
Rian Thornton
NPI 1255975389
$6,545.61
in general payments reported to CMS, 2019-2025
37 companies · $2,441 in 2025
The $2,441 reported for 2025 was more than what 96% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $375 · 2022: $973 · 2023: $1,260 · 2024: $1,496 · 2025: $2,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,825 · Education: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,824.86 |
| Education | $372.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $736.12 | 2022-2025 | Tagrisso, Imfinzi, Lynparza |
| Genzyme Corporation | $539.73 | 2022-2025 | |
| Beigene USA, INC. | $491.59 | 2023-2025 | Brukinsa |
| Janssen Biotech, INC. | $464.87 | 2024-2025 | Darzalex, Tecvayli, Erleada |
| Incyte Corporation | $433.23 | 2021-2025 | Monjuvi, Zynyz, Jakafi |
| E.R. Squibb & Sons, L.L.C. | $391.15 | 2023-2025 | Opdivo |
| Gilead Sciences, INC. | $371.49 | 2022-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $314.82 | 2022-2025 | Keytruda, Keytruda Qlex |
| Sobi, INC | $284.09 | 2025 | |
| Tactile Systems Technology INC | $205.94 | 2022 | |
| Daiichi Sankyo INC. | $196.55 | 2023-2025 | Enhertu, Datroway |
| Astellas Pharma US INC | $168.97 | 2024-2025 | Padcev |
| Eisai INC. | $153.99 | 2021-2024 | |
| Stemline Therapeutics INC. | $148.52 | 2023-2025 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $148.24 | 2022-2025 | Ninlaro |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $145.93 | 2023-2025 | Lunsumio, Polivy |
| Bayer Healthcare Pharmaceuticals INC. | $142.91 | 2025 | |
| G1 Therapeutics, INC. | $125.00 | 2021 | |
| Exelixis INC. | $125.00 | 2022 | |
| Celgene Corporation | $117.43 | 2024-2025 | Reblozyl, Opdualag |
| Novartis Pharmaceuticals Corporation | $101.85 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $98.71 | 2022 | |
| Seagen INC. | $92.99 | 2025 | |
| Pfizer INC. | $92.73 | 2024 | |
| Glaxosmithkline, LLC. | $53.86 | 2024-2025 | Ojjaara |
| Abbvie INC. | $53.40 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $44.48 | 2024-2025 | Onivyde, Somatuline Depot |
| Coherus Oncology, INC. | $31.42 | 2024 | |
| Taiho Oncology, INC. | $29.45 | 2025 | |
| Adaptive Biotechnologies Corporation | $28.61 | 2025 | Clonoseq |
| Tempus Ai, INC | $24.26 | 2024 | Xt Cdx |
| Accord Healthcare, INC. | $23.26 | 2024 | |
| Puma Biotechnology, INC. | $20.72 | 2024 | |
| Aveo Pharmaceuticals, INC. | $17.18 | 2025 | |
| Kyowa Kirin, INC. | $14.52 | 2025 | |
| Beone Medicines USA, INC. | $12.61 | 2025 | Brukinsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rian Thornton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.